Which drugs are used to treat hyperkalemia in acute renal failure?

Treatment of Hyperkalemia in Acute Renal Failure

For life-threatening hyperkalemia in acute renal failure, immediately administer IV calcium (calcium chloride 500-1000 mg or calcium gluconate 15-30 mL over 2-5 minutes) to stabilize the cardiac membrane, followed by insulin with glucose (10 units regular insulin with 25-50g glucose IV over 15-30 minutes) and nebulized salbutamol (10-20 mg) to shift potassium intracellularly, then initiate potassium removal with loop diuretics (furosemide 40-80 mg IV) or hemodialysis if refractory. 1, 2

Algorithmic Approach by Severity

Severe Hyperkalemia (K+ >6.0 mEq/L or ECG Changes)

Step 1: Cardiac Membrane Stabilization (Immediate - within 2-5 minutes)

• Calcium chloride 10%: 5-10 mL (500-1000 mg) IV over 2-5 minutes, OR
• Calcium gluconate 10%: 15-30 mL IV over 2-5 minutes
• Add hypertonic saline (3-5%) if concurrent hyponatremia 1, 2

Step 2: Intracellular Potassium Shift (Within 15-30 minutes)

• Insulin + Glucose: 10 units regular insulin IV with 25-50g glucose (50 mL D50) over 15-30 minutes 1, 2
• Nebulized salbutamol: 10-20 mg over 15 minutes (provides synergistic effect with insulin) 1, 2, 3
• Sodium bicarbonate: 50 mEq IV over 5 minutes ONLY if metabolic acidosis present 1, 2

Critical Pitfall: Insulin causes hypoglycemia in 20-75% of patients, particularly non-diabetics with low baseline glucose. Monitor glucose at 60,90,120 minutes post-administration. 4 The potassium-lowering effect is temporary (1-4 hours), and rebound hyperkalemia occurs after 2 hours, requiring definitive removal strategies. 1

Step 3: Potassium Removal (Initiate early)

• Loop diuretics: Furosemide 40-80 mg IV (if residual kidney function and not volume depleted) 1, 2
• Hemodialysis: Definitive treatment for refractory cases or anuric acute renal failure 1
• Potassium binders:
  • Sodium polystyrene sulfonate 15-50g PO/PR (falling out of favor due to GI adverse effects including colonic necrosis) 1, 5
  • Newer binders (patiromer or sodium zirconium cyclosilicate): More effective and better tolerated, though evidence in acute settings is emerging 1, 6, 7

Moderate Hyperkalemia (K+ 5.5-6.0 mEq/L, No ECG Changes)

• Insulin + glucose plus nebulized salbutamol for intracellular shift 1
• Loop diuretics if volume overloaded 1
• Consider potassium binders (newer agents preferred) 1, 6
• Address reversible factors: review medications (stop potassium-sparing diuretics, NSAIDs), correct metabolic acidosis, assess dietary intake 6, 7

Mild Hyperkalemia (K+ 5.0-5.5 mEq/L)

• Identify and correct reversible precipitants 6
• Consider loop diuretics if appropriate 1
• Initiate potassium binders if recurrent or non-reversible risk factors present 6, 7

Evidence Strength and Nuances

The 2018 European Heart Journal expert consensus 1 and 2010 AHA guidelines 2 provide the strongest framework. Notably, no RCTs demonstrate that these interventions reduce mortality or arrhythmias—the evidence base relies on their effectiveness at lowering serum potassium. 3

Comparative effectiveness: Salbutamol (10 mg nebulized) produces maximal effect at 120 minutes (mean decrease 1.29 mmol/L), while 20 mg produces peak effect at 90 minutes (decrease 1.18 mmol/L). 1 Insulin-dextrose and salbutamol have comparable efficacy, with combination therapy potentially superior. 8 Sodium bicarbonate is less effective than salbutamol (difference 0.46 mmol/L at 60 minutes) and should be reserved for patients with concurrent metabolic acidosis. 1, 4

Critical Clinical Considerations

Dialysis threshold: Hemodialysis remains the definitive treatment for severe, refractory hyperkalemia or when acute renal failure is anuric. 1, 2, 4

Monitoring requirements: Recheck potassium at 60,120, and 360 minutes post-treatment due to rebound hyperkalemia risk. 9, 4 In acute renal failure patients, expect 50% recurrence within 6-8 months if non-reversible risk factors persist. 6

Medication management: Do NOT discontinue renin-angiotensin-aldosterone system inhibitors (RAASi) reflexively—these drugs reduce mortality in heart failure and proteinuric kidney disease. Instead, use potassium binders, SGLT2 inhibitors (which reduce hyperkalemia risk by 16%), or switch to sacubitril/valsartan to maintain cardioprotective therapy. 10, 6, 11

Avoid: Sodium polystyrene sulfonate is no longer recommended as first-line due to questionable efficacy and risk of intestinal necrosis, particularly with sorbitol. 5, 4, 11